DLL4 represents an attractive target for cancer therapy since the blockade of DLL4/Notch signaling has been shown to cause non-productive tumor angiogenesis, to reduce the growth of VEGF-sensitive and resistant tumors, and to affect the CSC pool [221,222,223]. This evidence concerns the gene DLL4 and neoplasm.